Walleye Capital’s Celularity CELU Stock Holding History

Walleye Capital’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,810	Closed	-$332K	–	2393
2022 Q1	$332K	Buy	+3,810	New	+$228K	0.01%	1255

Other funds holding CELU

SIC

Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return

CVSC

C.V. Starr & Co New York $187M AUM 26.03% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Palantir Technologies Aventura, Florida $9.72M AUM 6.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LDFO

Louis-Dreyfus Family Office Wilton, Connecticut $64.7M AUM 21.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's CELU Position: Q2 2021 in Review

Walleye Capital sold out of Celularity (CELU) in Q2 2021, closing a stake of 1,800 shares — an estimated $181K sold.

Walleye Capital first reported a position in CELU in Q2 2020 and held it in 4 quarters. The position peaked at $1.29M in Q2 2020. 33 funds tracked by Wall St. Rank hold CELU as of Q2 2021.

Walleye Capital reported no remaining Celularity position as of Q2 2021 after selling out during the quarter.
Walleye Capital sold 1,800 Celularity shares in Q2 2021, an estimated $181K.
Walleye Capital first reported a position in Celularity in Q2 2020 and held it in 4 quarters.
Walleye Capital's Celularity position peaked at $1.29M in Q2 2020.
33 funds tracked by Wall St. Rank held Celularity as of Q2 2021.

Based on Walleye Capital's 13F filing for Q2 2021, filed 16 Aug 2021.